Cynomolgus CD32b / FCGR2B Protein (AVI Tag) , Biotinylated

Cynomolgus Fc-gamma RII-b / CD32b Protein

CD32b / FCGR2B Protein Product Information

• Synonym: CD32b
• Protein Construction: A DNA sequence encoding the Cynomolgus ( Macaca fascicularis ) CD32b ( AAL92097.1 ) extracellular domain ( Met 1 - Gly 220 ) was fused with a c-terminal polyhistidine tagged AVI tag at the C-terminus. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase ( BirA enzyme ) which is co-expressed
• Source: Cynomolgus
• Expression Host: Human Cells

CD32b / FCGR2B Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE
• mMB/mMP: 1.05
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Ala 45
• Molecular Mass: The recombinant cynomolgus CD32b consists of 211 amino acids and has a calculated molecular mass of 23.5 kDa. The apparent molecular mass of the recombinant protein is approximately 34 kDa in SDS-PAGE under reducing conditions due to glycosylation
• Formulation: Lyophilized from sterile PBS , pH 7.4
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: CD32b protein

CD32b / FCGR2B Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

CD32b / FCGR2B Protein Description

Cynomolgus low affinity immunoglobulin gamma Fc region receptor II-b, also known as IgG Fc receptor II-b, Fc-gamma RII-b, Fc-gamma-RIIb, CD32b and FCGR2B, is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD32b / FCGR2B is a receptor for the Fc region of complexed or aggregated immunoglobulins gamma. CD32b / FCGR2B is involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to CD32b / FCGR2B results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor.

An Fc receptor is a protein found on the surface of certain cells ( natural killer cells, macrophages, neutrophils, and mast cells ) that contribute to the protective functions of the immune system. Fc receptors bind to antibodies that are attached to infected cells or invading pathogens. Their activity stimulates phagocytic or cytotoxic cells to destroy microbes, or infected cells by antibody-mediated phagocytosis or antibody-dependent cell-mediated cytotoxicity. There are several different types of Fc receptors, which are classified based on the type of antibody that they recognize. Those that bind the most common class of antibody, IgG, are called Fc-gamma receptors (FcγR), those that bind IgA are called Fc-alpha receptors (FcαR) and those that bind IgE are called Fc-epsilon receptors (FcεR). All Fc-gamma receptors belong to the immunoglobulin superfamily and are the most important Fc receptors. This family includes several members, FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), which differ in their antibody affinities due to their different molecular structure.

References

1. Morcos M., et al.,1994, Kidney Int. 46:1627-34
2. Gessner, J.E. et al. 1995, Immunobiology. 193: 341-55
3. Firan M, et al.,2001, Int Immunol.13 (8): 993-1002
4. Takai, T., et al., 2002, Nature Rev. Immunol. 2: 580-92
5. Barnes, N. et al., 2002, Immunity. 16: 379-89
6. Galandrini R., et al.,2002, Blood.100: 4581-9
7. Kim, M-K. et al., 2003, Blood. 101: 4479-84
8. Nimmerjahn, F. et al., 2006, Immunity. 24:19-28
9. Webster, N.L. et al., 2006, J. Leukoc. Biol. 79: 294-302
10. Veri MC, et al., 2007, Immunology. 121 (3): 392-404